Strikingly, combined measurement of plasma TIA-1 and glial fibrillary acidic protein (GFAP) improved differentiation of AD subtypes, particularly distinguishing rpAD from non-rpAD cases. This evidence concerns the gene TIA1 and Alzheimer disease.